Celgene Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Celgene Corporation - Product Pipeline Review - 2016', provides an overview of the Celgene Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Celgene Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Celgene Corporation - The report provides overview of Celgene Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Celgene Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Celgene Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Celgene Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Celgene Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Celgene Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Celgene Corporation Snapshot 6 Celgene Corporation Overview 6 Key Information 6 Key Facts 6 Celgene Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 Celgene Corporation - Pipeline Review 15 Pipeline Products by Stage of Development 15 Pipeline Products - Monotherapy 16 Pipeline Products - Partnered Products 17 Pipeline Products - Out-Licensed Products 20 Celgene Corporation - Pipeline Products Glance 22 Celgene Corporation - Late Stage Pipeline Products 22 Celgene Corporation - Clinical Stage Pipeline Products 24 Celgene Corporation - Early Stage Pipeline Products 26 Celgene Corporation - Drug Profiles 28 apremilast 28 lenalidomide 31 azacitidine 36 CC-90007 40 mongersen 43 paclitaxel albumin bound 44 pomalidomide 48 romidepsin 53 amrubicin hydrochloride 56 CC-11050 58 CC-220 59 GI-6207 61 GI-6301 63 PDA-002 64 spebrutinib besylate 65 Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy 67 CC-122 68 CC-223 70 PNK-007 71 CC-115 72 CC-90001 73 CC-90002 74 CC-90003 75 CC-90005 76 Cellular Immunotherapy to Target GD2 for Neuroblastoma 77 CTP-730 78 pinometostat 79 AVL-181 81 AVL-192 82 CC-0730671 83 CC-2142 84 CC-509 85 CC-539 86 Monoclonal Antibody 1 for Inflammation 87 Monoclonal Antibody 2 for Inflammation 88 Small Molecules for Undisclosed Indication 89 Small Molecules to Agonize ROR gamma for Breast Cancer 90 Antibody for Oncology 92 Antibody for Undisclosed Indication 93 CC-0739623 94 CC-2141 95 CC-90006 96 CC-90008 97 CC-90009 98 CC-90010 99 CC-90011 100 CSC-1 101 Drug for Hematological Disorders and Oncology 102 Drug to Inhibit Kinase for Inflammation 103 Drugs for Hematology and Oncology 104 Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS 105 Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation 106 Small Molecules for Inflammation 107 Small Molecules for Inflammation and Cancer 108 Small Molecules for Malaria 109 Celgene Corporation - Pipeline Analysis 110 Celgene Corporation - Pipeline Products by Target 110 Celgene Corporation - Pipeline Products by Route of Administration 112 Celgene Corporation - Pipeline Products by Molecule Type 113 Celgene Corporation - Pipeline Products by Mechanism of Action 114 Celgene Corporation - Recent Pipeline Updates 116 Celgene Corporation - Dormant Projects 157 Celgene Corporation - Discontinued Pipeline Products 160 Discontinued Pipeline Product Profiles 160 Celgene Corporation - Company Statement 161 Celgene Corporation - Locations And Subsidiaries 162 Head Office 162 Other Locations & Subsidiaries 162 Appendix 168 Methodology 168 Coverage 168 Secondary Research 168 Primary Research 168 Expert Panel Validation 168 Contact Us 168 Disclaimer 169
List of Tables
Celgene Corporation, Key Information 10 Celgene Corporation, Key Facts 10 Celgene Corporation - Pipeline by Indication, 2016 12 Celgene Corporation - Pipeline by Stage of Development, 2016 19 Celgene Corporation - Monotherapy Products in Pipeline, 2016 20 Celgene Corporation - Partnered Products in Pipeline, 2016 21 Celgene Corporation - Partnered Products/ Combination Treatment Modalities, 2016 22 Celgene Corporation - Out-Licensed Products in Pipeline, 2016 24 Celgene Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 25 Celgene Corporation - Pre-Registration, 2016 26 Celgene Corporation - Phase III, 2016 27 Celgene Corporation - Phase II, 2016 28 Celgene Corporation - Phase I, 2016 29 Celgene Corporation - Preclinical, 2016 30 Celgene Corporation - Discovery, 2016 31 Celgene Corporation - Pipeline by Target, 2016 114 Celgene Corporation - Pipeline by Route of Administration, 2016 116 Celgene Corporation - Pipeline by Molecule Type, 2016 117 Celgene Corporation - Pipeline Products by Mechanism of Action, 2016 118 Celgene Corporation - Recent Pipeline Updates, 2016 120 Celgene Corporation - Dormant Developmental Projects,2016 161 Celgene Corporation - Discontinued Pipeline Products, 2016 164 Celgene Corporation, Other Locations 166 Celgene Corporation, Subsidiaries 166
List of Figures
Celgene Corporation - Pipeline by Top 10 Indication, 2016 12 Celgene Corporation - Pipeline by Stage of Development, 2016 19 Celgene Corporation - Monotherapy Products in Pipeline, 2016 20 Celgene Corporation - Partnered Products in Pipeline, 2016 21 Celgene Corporation - Out-Licensed Products in Pipeline, 2016 24 Celgene Corporation - Pipeline by Top 10 Target, 2016 114 Celgene Corporation - Pipeline by Route of Administration, 2016 116 Celgene Corporation - Pipeline by Molecule Type, 2016 117 Celgene Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016 118
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.